Slow Capital Inc. Purchases 47 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Slow Capital Inc. increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,844 shares of the biopharmaceutical company’s stock after buying an additional 47 shares during the quarter. Regeneron Pharmaceuticals accounts for 1.8% of Slow Capital Inc.’s portfolio, making the stock its 14th largest position. Slow Capital Inc.’s holdings in Regeneron Pharmaceuticals were worth $10,402,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of REGN. Ronald Blue Trust Inc. grew its stake in Regeneron Pharmaceuticals by 18.8% in the third quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 12 shares during the period. Drive Wealth Management LLC grew its stake in Regeneron Pharmaceuticals by 4.0% in the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 12 shares during the period. Cassia Capital Partners LLC grew its stake in Regeneron Pharmaceuticals by 2.3% in the third quarter. Cassia Capital Partners LLC now owns 589 shares of the biopharmaceutical company’s stock worth $485,000 after purchasing an additional 13 shares during the period. Sutton Wealth Advisors Inc. grew its stake in Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 13 shares during the period. Finally, Clearview Wealth Advisors LLC grew its stake in Regeneron Pharmaceuticals by 1.5% in the fourth quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock worth $751,000 after purchasing an additional 13 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded up $14.47 during trading on Wednesday, reaching $908.61. The stock had a trading volume of 160,401 shares, compared to its average volume of 491,262. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $998.33. The stock’s 50 day moving average is $955.94 and its two-hundred day moving average is $890.45. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The firm has a market cap of $99.73 billion, a PE ratio of 25.73, a PEG ratio of 2.62 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter in the prior year, the company earned $10.96 earnings per share. Regeneron Pharmaceuticals’s revenue was up .6% on a year-over-year basis. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.18 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the transaction, the director now owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,729 shares of company stock valued at $13,124,641. 8.83% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on REGN. BMO Capital Markets upped their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Barclays increased their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. Royal Bank of Canada reissued an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. Finally, Truist Financial reissued a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $970.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.